@article{15bc637ca23d41babbd8ebe2e8e199fe,
title = "Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction",
author = "Fung, \{Anthony Y.\} and Gerald Lorch and Cambier, \{Patrick A.\} and Dennis Hansen and Titus, \{Bradley G.\} and Martin, \{Jenny S.\} and Lee, \{Jennifer J.\} and Every, \{Nathan R.\} and Hallstrom, \{Alfred P.\} and Donna Stock-Novack and Joel Scherer and W.Douglas Weaver",
note = "Background: Previous clinical studies have shown that direct antithrombins can accelerate clot lysis after treatment with streptokinase in acute myocardial infarction (MI). Efegatran is a new direct antithrombin, which in experimental animals has been shown to enhance thrombolysis, reduce rate of reocclusion, and limit infarct size.",
year = "1999",
month = oct,
day = "1",
doi = "10.1016/S0002-8703(99)70185-7",
language = "American English",
volume = "138",
journal = "American Heart Journal",
issn = "1097-6744",
number = "4",
}